Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 15/20 | 0.52 |
| ▸ | TMPRSS15 | P98073 | 11/20 | 0.52 |
| ▸ | F2 | P00734 | 3/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.47 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.46 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.46 |
| ▸ | ACR | P10323 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.45 |
| ▸ | KLK1 | P06870 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18720209 | 1.00 | PRSS1 (0.52) | PRSS1TMPRSS15F2PRSS2PRSS3 | |
| SCHEMBL20008695 | 0.89 | PRSS1 (0.52) | PRSS1TMPRSS15F2ST14TMPRSS2 | |
| SCHEMBL18720221 | 0.88 | F12 (0.60) | PRSS1F2PRSS2PRSS3ST14 | |
| SCHEMBL20008699 | 0.85 | KMT2A (0.48) | PRSS1F2PRSS2PRSS3ACR | |
| SCHEMBL18720203 | 0.85 | KMT2A (0.48) | PRSS1F2PRSS2PRSS3ACR | |
| SCHEMBL21119466 | 0.85 | TMPRSS15 (0.47) | PRSS1TMPRSS15F2PARP10 | |
| SCHEMBL20008710 | 0.83 | PRSS1 (0.51) | PRSS1TMPRSS15F2PRSS2PRSS3 | |
| SCHEMBL8224852 | 0.83 | PRSS1 (0.57) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL20008707 | 0.82 | PRSS1 (0.71) | PRSS1TMPRSS15F2PRSS2PRSS3 | |
| SCHEMBL17236361 | 0.82 | MAPT (0.64) | PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885TMPRSS15 87/4885F2 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.